课题基金 / 基金详情

INTERACTION OF DILTIAZEM & VERAPAMIL WITH SIMVASTATIN

INTERACTION OF DILTIAZEM & VERAPAMIL WITH SIMVASTATIN
地尔硫卓的相互作用
批准号：
6265102
负责人：
D CRAIG BRATER
金额：
$0.04万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6265102
关键词：
antihypercholesterolemic agent clinical research clinical trial phase I cytochrome P450 diltiazem drug interactions human subject human therapy evaluation pharmacokinetics verapamil

项目摘要

项目成果

D CRAIG BRATER的其他基金

相似基金

相关文献

中文摘要
翻译
辛伐他汀和洛伐他汀一样，通过细胞色素P450 3A4(细胞色素P450 3A4)转化为活性代谢物。我们已经证明洛伐他汀对一种常用的钙拮抗剂地尔硫卓的相互作用很敏感，众所周知，地尔硫卓具有阻断细胞色素P3A4的能力。维拉帕米同样可以阻断这种酶。目前的研究是为了量化地尔硫卓和维拉帕米与辛伐他汀的相互作用，因为这两种钙拮抗剂中的任何一种都可能经常与辛伐他汀联合使用。
英文摘要
Simvastatin, like lovastatin is converted to active metabolites by cytochrome P450 3A4 (CYP3A4). We have shown that lovastatin is susceptible to interactions with a commonly used calcium antagonist, diltiazem, that is known to have the capacity to block CYP3A4. Verapamil can similarly block this enzyme. The current study is to quantify the interaction of diltiazem and of verapamil with simvastatin since combinations of either of these calcium antagonists with simvastatin are likely to occur frequently.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Diuretics on Response to Torsemide in Patients with Congestive Heart Failure
General Clinical Research Ctr:Pharmacogenetics Core Supp
MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE AND COMPARE
MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE AND COMPARE
海外基金